(Q33395375)

English

Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1 reference

based on heuristic

inferred from title

author name string

Jens Samol

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Malcolm Ranson

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Edwina Scott

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Euan Macpherson

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

James Carmichael

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Anne Thomas

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

James Cassidy

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

18 May 2011

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Investigational New Drugs

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

30

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1493-1500

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

https://scigraph.springernature.com/pub.10.1007/s10637-011-9682-9

0 references

Genome maintenance mechanisms for preventing cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9682-9

21 January 2018

The therapeutic potential of poly(ADP-ribose) polymerase inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9682-9

21 January 2018

4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9682-9

21 January 2018

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9682-9

21 January 2018

Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9682-9

21 January 2018

Sensitivity and acquired resistance of BRCA1;p53-deficient mouse mammary tumors to the topoisomerase I inhibitor topotecan

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9682-9

21 January 2018

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9682-9

21 January 2018

Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9682-9

21 January 2018

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9682-9

21 January 2018

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9682-9

21 January 2018

Topotecan - A novel topoisomerase I inhibitor: pharmacology and clinical experience

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9682-9

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9682-9

21 January 2018

Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9682-9

21 January 2018

What makes tumors multidrug resistant?

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9682-9

21 January 2018

Resistance to therapy caused by intragenic deletion in BRCA2

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9682-9

21 January 2018

Induction of P-glycoprotein expression and function in human intestinal epithelial cells (T84).

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9682-9

21 January 2018

Development of a real-time in vivo transcription assay: application reveals pregnane X receptor-mediated induction of CYP3A4 by cancer chemotherapeutic agents

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9682-9

21 January 2018

Iniparib plus chemotherapy in metastatic triple-negative breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9682-9

21 January 2018

Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21590367

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10637-011-9682-9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33395375&oldid=1991204929"